The CHST14 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population generated from the human Raji B lymphocyte line. The product features targeted disruption of the CHST14 gene, which encodes carbohydrate sulfotransferase 14, a key enzyme in chondroitin and dermatan sulfate sulfation. This polyclonal pool provides a heterogeneous loss-of-function model, allowing robust assessment of CHST14-dependent functions without clonal selection artifacts.
Raji cells are an EBV-positive Burkitt??s lymphoma-derived B-cell line widely used to study B-cell biology and lymphomagenesis. These lymphoblastoid cells exhibit surface immunoglobulin expression and antigen-presenting capability, making them suitable for immunological assays. Raji cells express a repertoire of proteoglycans and sulfotransferases, enabling investigation of glycosaminoglycan modifications in a lymphoid environment where extracellular matrix interactions can modulate immune cell behavior.
CHST14, also known as C4ST-1, transfers sulfate to the C4 position of N-acetylgalactosamine residues in chondroitin/dermatan sulfate chains using PAPS as co-factor. This sulfation is critical for proteoglycan function, particularly of decorin and biglycan, which regulate collagen assembly and growth factor signaling. Upstream regulators include TGF-??1, SOX9, and BMP signaling, while downstream targets encompass TGF-?? activity, FGF2, and collagen fibrillogenesis. Disruption of CHST14 thus ablates specific sulfation patterns, impairing matrix organization and signaling networks.
In Raji B cells, CHST14 knockout enables dissection of cell-intrinsic sulfation roles. Although not classical ECM producers, B lymphocytes interact with sulfated proteoglycans that influence adhesion, migration, and cytokine presentation. Loss of CHST14 may alter TGF-?? and FGF2 sequestration, affecting lymphoma microenvironment dynamics. This model also provides a platform to study how CHST14 deficiency, associated with musculocontractural Ehlers-Danlos syndrome, influences immune cell function in connective tissue disorders.
Researchers can employ these cells to measure CHST14 expression and dermatan sulfate content via Western blot, RT-qPCR, and immunofluorescence; perform proteoglycan analysis by HPLC; and assess cell surface proteoglycans by flow cytometry. Functional assays include migration, invasion, and proliferation. Transcriptomic changes are detectable by RNA-seq, and TGF-?? pathway activity can be monitored with reporter assays. The cells are suitable for drug screening targeting sulfotransferases and for modeling Ehlers-Danlos syndrome defects. For further details, contact Ascent Research.
